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Available online 9 March 2017To date many clinical studies aim to increase the number and/or ﬁtness of CD4+CD127lowCD25+ regulatory T
cells (Tregs) in vivo to harness their regulatory potential in the context of treating autoimmune disease. Here,
we sought to deﬁne the phenotype and function of Tregs expressing the highest levels of IL-6 receptor (IL-6R).
We have identiﬁed a population of CD4+CD127lowCD25+ TIGIT− T cells distinguished by their elevated IL-6R ex-
pression that lacked expression of HELIOS, showed higher CTLA-4 expression, and displayed increased suppres-
sive capacity compared to IL-6RhiTIGIT+ Tregs. IL-6RhiTIGIT− CD127lowCD25+ T cells contained amajority of cells
demethylated at FOXP3 and displayed a Th17 transcriptional signature, including RORC (RORγt) and the capacity
of producing both pro- and anti-inﬂammatory cytokines, such as IL-17, IL-22 and IL-10. We propose that in vivo,
in the presence of IL-6-associated inﬂammation, the suppressive function of CD4+CD127lowCD25+ FOXP3+IL-
6RhiTIGIT− T cells is temporarily disarmed allowing further activation of the effector functions and potential
pathogenic tissue damage.Human Genetics
erreira),
. This is an open a©2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
CD4+CD127lowCD25+ regulatory T cells (Tregs), the majority of
which differentiate in, and egress from, the thymus are an immune sub-
set with a critical role in the maintenance of self-tolerance and protec-
tion against tissue damage and autoimmunity [1]. This Treg subset is
deﬁned by the expression of the transcription factor FOXP3,which is es-
sential for their differentiation,maintenance and function [2]. The stable
FOXP3 expression that is required for Treg function depends on de-
methylation of a sequence in the ﬁrst intron of the gene, termed the
Treg-speciﬁc demethylated region (TSDR) [3]. FOXP3, along with
other transcription factors, suppresses the expression of the IL-2 gene
in these Tregs [2,4], making them critically dependent on IL-2 produc-
tion from conventional or effector T cells (Teffs). For example, reduction
of IL-2 in the pancreatic islets leads to a loss of FOXP3 expression and
Treg numbers in a mouse model of autoimmune type 1 diabetes
(T1D) [5,6]. Furthermore, in humans, variation of genes in the IL-2, University of
ccess article underpathway, for example IL2RA encoding CD25, alters susceptibility to au-
toimmune diseases, including T1D [7–10]. The leading disease-
associated variant of IL2RA is correlated with reduced expression of
CD25, leading to a decrease in Treg IL-2 sensitivity and suppressive abil-
ity [11,12].
Theseﬁndings have provided the rationale for clinical studies aiming
at expanding Tregs in vitro, or increasing Treg numbers and ﬁtness
in vivoby IL-2 administration, for the treatment of autoimmunediseases
[13–15]. However, there is growing evidence of heterogeneity and plas-
ticity among Tregs [16–18]. A population of FOXP3+ Tregs has been
identiﬁed in humans that constitutively expresses the Th17 lineage-
speciﬁc transcription factor RORγt, a portion of which produce IL-17
upon in vitro activation [19–22]. More recently, two studies have dem-
onstrated that the frequency of mouse RORγt+ FOXP3+ Th17 Tregs in
the colon is determined by the composition of the intestinal commensal
microbiota [23,24]. These data indicate that Th17 Tregs play a key role in
the regulation of the intestinal Th17 immune responses to commensal
and pathogenic bacteria, while preventing inﬂammation. Consistent
with this hypothesis, adoptive transfer of RORγt+ FOXP3+ Th17 Tregs
completely abrogated the development of inﬂammation in a mouse co-
litis model, and displayed increased suppressive capacity in vivo com-
pared to conventional RORγt− FOXP3+ Tregs [25]. Further supportingthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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showed that a subset of FOXP3intRORγt+ Tregs were able to prevent
the development of autoimmune diabetes in the NOD model [26]. The
mutually opposing regulatory functions of the FOXP3 and RORγt tran-
scription factors have raised questions regarding the origin and differ-
entiation of Th17 Tregs, leading to the hypothesis that Th17 T effector
cells (Teff) and Tregs could share a similar differentiation pathway,
and have been selected to ensure immunity at the barrier surfaces and
the adaptation of the host to commensal bacteria [27].
IL-6, which is a potent driver of inﬂammatory disease, is instrumen-
tal for the commitment to the Th17 lineage, by inhibiting FOXP3-
mediated suppression of RORγt, thereby promoting the differentiation
of the Th17 Teff lineage in mice [28–30]. In addition, studies in mice
have also shown that IL-6 signalling is an established factor to inhibit
the suppressive function of Tregs [31], although this effect has been
shown to be Treg extrinsic, through the activation of Teffs, which are
able to escape Treg suppression [32]. Furthermore, in the presence of
IL-6, Tregs have been reported to induce IL-17 production by Th17
Teffs cells and have been shown to be themselves capable of producing
IL-17 [33].
The effects of IL-6 in studies of human CD4+ T cells differ from those
reported using cells frommice in several aspects. For example, IL-6 does
not contribute to the differentiation of naïve CD4+ T cells to the Th17
lineage as it can in mice, although IL-1β and IL-6 together induce IL-
17A secretion from humanmemory CD4+ Th17 cells [34]. Furthermore,
the exact role of IL-6 signalling on human Treg function remains uncer-
tain. In psoriasis patients, elevated IL-6 production in affected skin has
been suggested to promote the differentiation of IL-17-producing path-
ogenic Th17 cells and reduce the suppressive capacity of Tregs, although
this latter effect is likely to be indirect [35]. Evidence from Bhela et al.
also supports the hypothesis that Tregs are not the direct target of IL-6
for its ability to elicit resistance to Treg-mediated suppression [36]. In
contrast, Bending et al. have reported that IL-6 provides pro-
regulatory signals directly to human Tregs [37].
Previously, a genetic variant in IL6R (rs2228145 ANC; Asp358Ala)
has been associated with human inﬂammatory diseases, including
T1D [38], ankylosing spondylitis [39] and rheumatoid arthritis [40], pre-
sumably due to a greater expression of the IL-6 receptor and therefore a
higher IL-6 signalling capacity in CD4+ Teffs expressing the common
Asp358 susceptibility allele compared to Ala358 [38]. Furthermore, IL-
6 signalling is increased in T1D patients owing to increased IL-6R ex-
pression [41]. These results indicate that inhibition of IL-6 signalling
could be a therapeutic approach in T1D, as it is in other human inﬂam-
matory diseases [42,43]. Nevertheless, blockade of IL-6, which is a key
pathway in immune defence, could raise the risk of serious infections
in T1D patients and hence targeting the therapy to a speciﬁc cell type
could offer advantages in therapy. In the current study we show that a
portion of thememory IL-6Rhi CD127lowCD25+ T cells (here designated
as Tregs) lack TIGIT and HELIOS expression and have a constitutively el-
evated expression of the effector Tregmarker CTLA-4, and contain a het-
erogeneous group of cells that as a total population are highly
suppressive, with portions expressing a Th17 signature, a demethylated
FOXP3 TSDR and the FOXP3 transcription factor protein. IL-6Rhi TIGIT−
Tregs contain a subset of cells having a tissue-homing chemokine recep-
tor proﬁle analogous to the intestinal FOXP3+RORγt+ Th17 Treg subset
recently characterised in mice [23–25]. We also show that, similarly to
other Treg subsets, circulating IL-6Rhi Tregs were expanded in number
after administration of IL-2. These data indicate that IL-6Rhi TIGIT−
Tregs will be highly sensitive to the endogenous production of IL-2 in-
duced by infection or inﬂammation, thereby stimulating the recruit-
ment of these highly suppressive Tregs, which we suggest could be
normally resident in the intestine and mesenteric lymph nodes, to
sites of infected cells or inﬂammation,where these Tregs curtail effector
activities and prevent potentially pathogenic tissue damage. However,
in the presence of high tissue concentrations of IL-6 these cells might
lose their suppressive capacity temporarily to help ﬁght infection, aneffect that would not be advantageous in a site of chronic inﬂammation
in which a pathogen was not present. With the combination of surface
markers we have deﬁned here, these cells can now be puriﬁed from
whole blood and biopsy tissues to further study their functions and
their putative immunotherapeutic properties.
2. Materials and methods
2.1. Subjects and study design
Patient selection and the protocol for the “Adaptive study of IL-2 dose
on regulatory T cells in type 1 diabetes” (DILT1D) has been published pre-
viously [15,44]. A subset of 22 T1D patients (median age = 26, range
18–48) were selected for this study, and assessed for the expression of
IL-6R on Tregs. A blood sample was taken before treatment to establish
baseline Treg frequencies and phenotypes, followed by subcutaneous
administration of a single dose of recombinant human IL-2 (Proleukin/
aldesleukin; dose range 45,000–737,000 IU/m2) on day 0. The patients
were bled 90 min after treatment, and then daily to day 4 and at days
7, 9, 14, 21 and 60. The DILT1D data from individuals prior to normalisa-
tion as a group are available, however they cannot be anonymised suf-
ﬁciently to be able to put into the public domain without risk of
participant identiﬁcation. Data are available on request, through the
Cambridge University institutional repository (DOI link: https://doi.
org/10.17863/CAM.832).
Study participants for all further immunophenotyping and function-
al assays included in this study were adult healthy volunteers recruited
from the Cambridge BioResource (http://www.cambridgebioresource.
org.uk/). All samples were collected after approval from the relevant re-
search ethics committees, and written informed consent was obtained
from the participants.
2.2. Flow cytometry
For the clinical trial participants, 30 ml whole blood were collected
into lithium heparin tubes and processed within 4 h of phlebotomy.
Immunostaining was performed in whole blood with speciﬁc
ﬂuorochrome-conjugated antibodies (Table 1 in Ref. [45]) at room tem-
perature for 45 min. IL-6R expression was assessed using a phycoery-
thrin (PE)-conjugated antibody, which provided the better resolution
in our ﬂow cytometric setting. This was critical to increase the sensitiv-
ity of the assay, and assess quantitative differences in IL-6R expression
in different T cell subsets.
Treg immunophenotyping in healthy donors was performed in
fresh peripheral blood mononuclear cells (PBMCs) isolated by Ficoll
gradient centrifugation (Lymphoprep; STEMCELL Technologies)
from whole blood within 2 h of phlebotomy. Cells were stained
with ﬂuorochrome-conjugated antibodies against surface receptors
(Table 1 in Ref. [45]) for 45min at 4 °C. Fixation and permeabilisation
was performed using FOXP3 Fix/Perm Buffer Set (BioLegend) and
cells were then stained with the respective intracellular antibodies
for 45 min at room temperature (Table 1 in Ref. [45]).
2.3. Cytokine secretion assays
To assess cytokine production, CD4+ T cells were isolated from
whole blood by negative selection using RosetteSep (STEMCELL
Technologies) within 2 h of phlebotomy. Cells were resuspended in
X-Vivo15 (Lonza) + 5% heat-inactivated, ﬁltered human AB serum
(Sigma), and cultured (1–2 × 106 CD4s/well) in a 24-well ﬂat-bottom
cell culture plate (CELLSTAR, Greiner) at 37 °C in the presence or
absence of the 1× Cell Stimulation Cocktail (eBiosiences), containing
phorbol myristate acetate (PMA), ionomycin, and protein transport
inhibitors (brefeldin A and monensin).
After 6 h culture, cells were harvested and immunostainedwith sur-
face and intracellular antibodies (Table 1 in Ref. [45]). The unstimulated
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Dead-cell exclusion was performed using the eFluor780 Fixable Viabili-
ty Dye (eBiosciences).2.4. Intracellular pSTAT3 immunostainings
PBMCs were isolated from three healthy donors by Ficoll gradient
centrifugation from whole blood within 2 h of phlebotomy. IL-6 sensi-
tivity of the memory Treg and Teff subsets was determined by intracel-
lular pSTAT3 immunostaining in freshly isolated PBMCs in response to
IL-6 stimulation in vitro, as previously described [38].2.5. Cell sorting
Cell sorting was performed using a BD FACSAria Fusion ﬂow
cytometer (BD Biosciences) after pre-enrichment of CD4+ T cells from
whole blood by negative selection. Fluorescence-conjugated antibodies
used for sorting are described in Table 1 in Ref. [45]. Sorting efﬁciencies
were determined in four donors, based on IL-6R and TIGIT expression
and ranged between 90 and 99%.2.6. FOXP3 and CTLA4 demethylation assays
Epigenetic proﬁling of the FOXP3 TSDR and the CTLA-4 gene was
performed using a next-generation sequencing method described pre-
viously [46]. DNAwas extracted from ﬂow sorted cells from three inde-
pendent healthy male donors (containing a single copy of the FOXP3
gene on chromosome X) and bisulﬁte treated using Epitect fast lyse all
kit (Qiagen). Bisulﬁte treated DNA samples were used as the template
for ﬁrst round PCR of the FOXP3 TSDR (ChrX: 49,260,689–49,260,861)
and CTLA4 exon 2 locus (Chr2: 203,870,594–203,870,872). A second
round PCR was performed to add a bar code sequence, before samples
were pooled and sequenced on an Illumina MiSeq.2.7. In vitro proliferation and suppression assays
To assess the suppressive capacity of IL-6RhiTIGIT−, IL-6RhiTIGIT+
and IL-6RloTIGIT+ Tregs, 104 sorted CD45RA−CD127+CD25− Teffs
were labelled with eFluor450 Cell Proliferation Dye (eBioscience), and
co-cultured with each Treg subset at various ratios (Treg:Teff 1:2 to
1:16) in X-Vivo15 + 5% human AB serum. Co-cultures were incubated
for 84 h at 37 °C in V-bottom 96-well cell culture plates (CELLSTAR,
Greiner) in the presence ofα-CD3/CD28 activation beads (Life Technol-
ogies), at a 1:20 bead:Teffs ratio. Proliferation of the responder cells was
assessed by the dilution of the proliferation dye by ﬂow cytometry.
For the proliferation assays, sorted cells were labelled with
eFluor450 Cell Proliferation Dye, and cultured in the presence of exoge-
nous IL-2 (100 U/ml; Proleukin) and α-CD3/CD28 activation beads, at a
1:1 bead:Teff ratio.
Proliferation and suppressive capacity were calculated using the
Division Index (DI) in FlowJo (Tree Star), setting 0% suppression as
the condition with the respective Teffs cultured in the absence of
Tregs. The DI represents the average number of cell divisions that
each seeding Teff cell has undergone andwas obtained using the following
equation:DI=Total number of Cell Divisions/Initial number of Teff cells in
culture = ððG12 Þ

1þ ðG24 Þ

2þ ðG38 Þ

3þ ðG416Þ

4þ…þ ð Gnn2Þ

n Þ=ðG0 þ ðG12 Þ þ
ðG24 Þ þ ðG38 Þ þ ðG416Þ þ…þ ð Gnn2ÞÞ, wheren represents the number of divisions
and G(n) represents the number of cells that have undergone n divisions.
The suppressive capacity of each experimental condition was obtained
using the following equation: %Suppression = 100− [(DIx/DI0)*100],
where DIx represents the Division Index of the tested experimental
condition and DI0 represents the Division Index of the control sample
with no Tregs in culture.2.8. Transcriptional proﬁling of the Treg subsets
Gene expression proﬁling was performed by NanoString, using the
pre-designed nCounter Human Immunology v2 Panel (NanoString
Technologies). The four assessed immune cell subsets were ﬂow sorted
as described above, and 25,000 cells were collected into RLT lysis buffer
(Qiagen) either: (i) directly ex vivo; or (ii) following in vitro stimulation
for 165 min in the presence or absence of 50 ng/ml PMA (Sigma-Al-
drich) and 500 ng/ml ionomycin (Sigma-Aldrich), without addition of
protein transport inhibitors. RNA from the ﬂow-sorted T cell subsets
was extracted using the RNAeasy Micro Plus kit (Qiagen), with gDNA
cleanup, following manufacturer's instructions. Total RNA samples
were then hybridised to the NanoString CodeSets, following
manufacturer's instructions. Expression levels were assessed using an
nCounter Flex instrument (NanoString Technologies). Data were proc-
essed using the nSolver Analysis Software following normalisation of
the raw read counts to the geometric mean of positive control spike-
ins, and the gene expression of 15 selected housekeeping genes
(ATG10, C14orf166, CD3E, CD46, G6PD, GPI, POLR1B, POLR2A, PSMB5,
PSMB10, PTPRC, SDHA, SKI, TOLLIP and TUBB) that were found to have
low variability on both the samples collected ex vivo and following
in vitro stimulation.
2.9. Statistical analyses
Statistical analyses were performed using Prism software
(GraphPad) and R (www.r-project.org.com). Statistical signiﬁcance
was assessed using a two-tailed non-parametric Mann-Whitney test.
Comparison of immune phenotypes between the assessed Treg subsets
from the same individual was performed using a two-tailed paired non-
parametric Wilcoxon signed rank test.
Differential expression of normalised NanoString transcriptional
data was calculated using a paired analysis with DESeq2 v1.12.3 [47],
with pre-set size factors equal to one for all samples. Adjusted P values
correspond to the false discovery rates (FDR) for differential expression,
computed after correcting P values formultiple testing. Amissing FDR is
reported for genes that were found to contain an expression outlier by
DESeq2 Cook's distance-based ﬂagging of P values, and thus excluded
from multiple testing.
3. Results
3.1. Frequency of IL-6Rhi Tregs is transiently increased by a single dose of
IL-2 in vivo
To investigate the effect of IL-2 on the expression of IL-6R on Tregs
in vivo, we performed a detailed immunophenotyping of the Treg com-
partment in 22 T1D patients following treatment with a single dose of
IL-2. Although we acknowledge the limitation of deﬁning Tregs with
the use of surface markers and the fact that human CD4+ CD127-
lowCD25+ T cells represent a heterogeneous population containing a
subset of activated Teff cells, for consistency, we here refer to CD4+
CD127lowCD25+ T cells as ‘Tregs’, as these represent the canonical sur-
facemarkers used for the isolation of humanTregs for functional studies
requiring viable cells.We deﬁned in this study IL-6Rhi or IL-6Rlo Tregs, as
the subset of total CD127lowCD25+ CD4+ T cells in the upper or lower
20th percentile of the IL-6R mean ﬂuorescent intensity (MFI) distribu-
tion, respectively (Fig. 1A in Ref. [45]). The IL-6Rhi gate was deﬁned in
each patient at the ﬁrst visit, before IL-2 treatment, and applied to
every subsequent visit. We observed clear differences in IL-6R expres-
sion in CD45RA− (memory) and CD45RA+ (naïve) Tregs, resulting in
an increased frequency of IL-6Rhi Tregs within memory (30.2%) com-
pared to naïve Tregs (2.1%; Fig. 1B in Ref. [45]). The expression of IL-
6R on the surface of memory Tregs translated into a similar sensitivity
to IL-6 signalling in vitro compared to memory Teffs, as assessed by
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(Fig. 2A–C in Ref. [45]).
We found that single doses of IL-2 ranging from 0.16 × 106 to
0.735 × 106 IU/m2 induced a 42.0% increase (P= 7.4 × 10−6; Fig. 1A)
in the frequency of IL-6Rhi Tregs 24 h after treatment; Fig. 1A, B). This ef-
fect was dose dependent, with patients receiving lower doses of IL-2
(0.04 × 106–0.45 × 106 IU/m2) showing only an 18.7% increase in the
frequency of IL-6Rhi Tregs (P = 4.9 × 10−3; Fig. 1A) at 24 h post-
treatment. Nevertheless, we note that even in patients treated with
the lower IL-2 dose, there was a signiﬁcant increase in the frequency
of IL-6Rhi Tregs (maximum increase = 20.1%, P= 0.023; Fig. 1A), indi-
cating that IL-6Rhi Tregs are extremely sensitive to IL-2. This response to
IL-2 was not restricted to the IL-6Rhi Treg compartment (Fig. 1C), and
was consistent with the expansion of total CD4+CD127lowCD25+
Tregs reported previously [15]. The IL-2-induced increase in IL-6Rhi
Treg frequency was sustained for up to three days after treatment in
patients receiving the higher doses (Fig. 1A), before returning to the
pre-treatment or baseline frequencies. Consistent with the previously
reported decreased frequency of Tregs out of total CD4+ T cells in circu-
lation 90 min post-treatment [15], we also observed a 10.8% reduction
of the total number of CD4+IL-6Rhi Tregs immediately after treatment
(Fig. 1C). This reductionwas less pronounced than in total CD4+CD127-
lowCD25+ Tregs (19.0%). The dose-dependent increase of IL-6Rhi cells
induced by IL-2 was restricted to Tregs, and was not observed in mem-
ory Teffs, or in naïve T cells (Fig. 3A, B in Ref. [45]), at least at the doses ofFig. 1. Single dose of IL-2 transiently increases the frequency of IL-6Rhi Tregs in vivo. (A) Data de
visit following IL-2 treatment compared to pre-treatment baseline (median= 20.0%; range: 19
in type 1 diabetes” (DILT1D). The IL-6Rhimeanﬂuorescence intensity (MFI) thresholdwas deﬁne
6R MFI distribution in total CD127lowCD25+ Tregs, and applied to each subsequent visit. P
0.04–0.045 × 106 U/ml (N= 8; depicted in black); or (ii) the higher IL-2 doses of 0.16–0.737
the IL-2-induced increase (58%) in the frequency of IL-6Rhi Tregs after 24 h of treatment with
depict the variation (Mean ± SEM) of the frequency of (i) IL-6Rhi Tregs (left panel) and (ii) C
the same cohort of patients. Median pre-treatment baseline frequencies were 1.45% (range
CD127lowCD25+ Tregs, respectively. The maximum increases over the baseline pre-treatmen
group. P values for the maximum increase in the frequency of the assessed parameter in res
Wilcoxon signed rank test comparing the frequencies observed at the timepoint where the m
values for the IL-2 dose-dependent effects were calculated using a two-tailed non-paramet
groups at each timepoint. *P b 0.05; **P b 0.01; ns = not signiﬁcant.IL-2 analysed. In addition to the increased frequency of IL-6Rhi Tregs, we
also found that IL-2 treatment induced a similar dose-dependent in-
crease in the surface expression of IL-6R expression on Tregs at the
MFI level (5.5% and 13.5% increase in the low-dose and high-dose
groups, respectively, at 24 h post-treatment, P = 3.8 × 10−3; Fig. 3C
in Ref. [45]), which would lead to an increased sensitivity to IL-6.
3.2. Elevated IL-6R expression deﬁnes a population of antigen-experienced
CD127lowCD25+ Tregs
To obtain further insight into the phenotype and putative function of
IL-6Rhi Tregs, we immunophenotyped the CD4+ CD127lowCD25+ T cell
compartment using freshly isolated PBMCs from 22 healthy donors
(Fig. 2A). The ﬁrst distinctive feature was that virtually all IL-6Rhi
Tregs were of the CD45RA− memory phenotype (93.2%). This was in
contrast with IL-6Rlo Tregs (26.9%, P= 4.4 × 10−17; Fig. 2B), indicating
that IL-6Rhi Tregs have been previously activated in tissues in response
to antigen. Given this bias in the frequency of CD45RA−memory cells,
for all further assays performed in this study, we normalised the
assessed T cell subsets to the CD45RA−memory compartment to com-
pare the phenotype and function of cells. Memory CD45RA− IL-6Rhi
CD127lowCD25+ T cells (henceforth designated asmTregs) also showed
increased proliferative activity compared with their CD45RA− IL-6Rlo
counterparts, as assessed by the frequency of Ki-67+ cells (30.2% versus
9.7%, P = 7.0 × 10−10), and increased frequency of the activationpict the variation (Mean± SEM) of the frequency of IL-6Rhi CD127lowCD25+ Tregs at each
.0–21.1%) in 22 T1D patients enrolled in the “Adaptive study of IL-2 dose on regulatory T cells
d on eachdonor at theﬁrst pre-treatment timepoints as theupper 20th percentile of the IL-
atients were stratiﬁed according to whether they received (i) the lower IL-2 doses of
× 106 U/ml (N = 14; depicted in red). (B) Histograms depict an illustrative example of
a single dose of 0.445 × 106 U/ml IL-2, compared to the pre-treatment baseline. (C) Data
D127+CD25− Tregs (right panel) among total CD4+ T cells following IL-2 treatment in
: 0.75–2.08%) and 7.75% (range: 3.96–10.64%) for CD4+ IL-6Rhi Tregs and total CD4+
t frequencies achieved during the course of the study are indicated for each IL-2 dosing
ponse to a single dose of IL-2 was calculated using a two-tailed paired non-parametric
aximal increase was achieved with the respective baseline pre-treatment frequencies. P
ric Mann-Whitney test comparing the frequency of IL-6Rhi cells between the two dose
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that the IL-6Rhi cells have been activated more recently.
The IL-6Rhi mTreg population has more cells that are not bone-ﬁde
Tregs than the IL-6Rlo subset since a higher proportion lacks FOXP3 ex-
pression (81.1% FOXP3+ versus 92.9%, P= 1.8 × 10−9). In addition, IL-
6Rhi mTregs also showed decreased frequencies of two other markers
associated with Tregs: HELIOS (51.9% versus 82.5%, P = 1.2 × 10−14)
and TIGIT (70.8% versus 92.2%, P = 8.9 × 10−9; Fig. 2D), indicating
that there ismore heterogeneity among the IL-6RhimTregs as compared
to IL-6Rlo mTregs. Although the frequency of cells expressing these Treg
markers is decreased in IL-6Rhi mTregs, we note that their expression
levels are very comparable on a per cell basis on the positive fraction
of these markers on both the IL-6Rhi and IL-6Rlo mTregs, as assessed
by their MFI levels (Fig. 2D).
3.3. Stratiﬁcation of the IL-6RhiTreg subset by TIGIT expression
To address the heterogeneity in IL-6Rhi mTregs, we stratiﬁed this
subset based on the expression of the surface-expressed co-inhibitory
receptor TIGIT (Fig. 3A). We observed a differential expression of IL-6R
between the two TIGIT-deﬁned mTreg subsets, with an increased fre-
quency of IL-6Rhi cells in the TIGIT− (45.6%), compared to TIGIT+
mTregs (24.3%; Fig. 1C in Ref. [45]). In contrast to IL-6Rhi mTregs, the
vast majority of IL-6Rlo mTregs were TIGIT+ (92.2%; Fig. 2D), and there-
fore are described henceforth as a subset of TIGIT+ mTregs.
We found that the observed reduction of HELIOS+ and FOXP3+ cells
within IL-6Rhi mTregs was restricted to the TIGIT− subset, and was par-
ticularly pronounced for the HELIOS transcription factor. IL-6RhiTIGIT−
mTregs showed a markedly lower frequency of HELIOS+ cells (10.0%),
compared to both IL-6RhiTIGIT+ (72.0%, P = 1.8 × 10−34) and IL-
6RloTIGIT+ mTregs (86.4%, P = 1.6 × 10−34; Fig. 3B). Similarly, IL-
6RhiTIGIT− mTregs showed a reduction in the frequency of
FOXP3+ cells (70.1%) compared to both IL-6RhiTIGIT+ (87.7%,
P = 1.9 × 10−15) and IL-6RloTIGIT+ mTregs (93.0%, P =
5.6 × 10−18; Fig. 3B). Although the majority of IL-6RhiTIGIT−
mTregs were FOXP3 protein-positive, we note that a signiﬁcant
fraction (29.9%, range: 10.9%–49.2%; Fig. 3B) of this subset is
FOXP3−, and therefore cannot be considered as conventional
Tregs.
IL-6RhiTIGIT−mTregs also showed some reduction in the surface ex-
pression of the IL-2 receptor (CD25) compared to their TIGIT+ counter-
parts (CD25 MFI = 2036 versus 2969, respectively, corresponding to a
31.4% reduction of CD25 expression; P = 6.7 × 10−16), but not com-
pared with IL-6RloTIGIT+ mTregs (CD25 MFI = 2189; Fig. 3C) and still
markedly higher than memory Teffs (Fig. 3B,C). In addition, IL-
6RhiTIGIT− mTregs were found to be almost completely positive for
CTLA-4 (90.9%), which is a key mediator of Treg suppressive func-
tion. This frequency was higher than IL-6RhiTIGIT+ mTregs (80.3%,
P = 2.7 × 10−5) and particularly pronounced when compared to
the IL-6RloTIGIT+ subset (58.6%, P= 1.9 × 10−6; Fig. 3C), suggesting
that IL-6RhiTIGIT− mTregs could also be suppressive in vivo.
3.4. IL-6RhiTIGIT− Tregs are highly suppressive in vitro and a majority are
demethylated at the FOXP3 TSDR
Flow-sorted puriﬁed IL-6RhiTIGIT−mTregs suppressed the prolifera-
tion of autologous memory Teff cells in vitro (Fig. 4A). We observed a
linear titration of the suppressive capacity of the three Treg subsets
with decreasing Treg:Teff ratios, with IL-6RhiTIGIT− Tregs showing
higher suppressive capacity than conventional IL-6RloTIGIT+ Tregs,
and even higher suppressive capacity than IL-6RhiTIGIT+ mTregs
(Fig. 4A). The proportion of the IL-6RhiTIGIT− mTreg population
demethylated at the FOXP3 TSDR (54.2%), which is a hallmark of Tregs
that maintain stable FOXP3 expression, was less than the proportion ex-
pressing FOXP3 protein (70.1%; Fig. 3B). The remainder were methylat-
ed at FOXP3, which is in contrast with the other two conventional Tregsubsets, in which nearly all of the cells (N92%) were demethylated at
the FOXP3 TSDR (Fig. 4B). The IL-6RhiTIGIT− Treg population also
showed 90.6% demethylation of a sequence in exon 2 of CTLA4
(Fig. 4B), which was almost identical to IL-6RhiTIGIT+ (92.0%) and IL-
6RloTIGIT+ (89.0%) mTregs, but in marked contrast to memory Teff
cells, in which only 37.4% of cells were demethylated at this region of
CTLA4 (Fig. 4B).
Next, we investigatedwhether the Treg subsets were anergic to TCR
stimulation (anti-CD3/anti-CD28),when cultured in vitro in the absence
or presence of a high dose of IL-2 (100U/ml). Consistentwith their Treg
phenotypes, all three mTreg subsets, IL-6RhiTIGIT−, IL-6RhiTIGIT+ and
IL-6RloTIGIT+mTregs were almost completely anergic to T cell stimula-
tion, as compared to memory Teffs (Fig. 3 in Ref. [45]). In the pres-
ence of IL-2, and in contrast to the IL-6RhiTIGIT+ and IL-6RloTIGIT+
mTregs, IL-6RhiTIGIT− mTregs showed modest capacity to prolifer-
ate, although much less than conventional memory Teffs (Fig. 4C).
The ability of a majority of IL-6RhiTIGIT− mTregs to proliferate
using stimulus conditions that are unable to induce a proliferative re-
sponse from IL-6RhiTIGIT+ and IL-6RloTIGIT+ mTregs suggests that
Teffs are present in the IL-6RhiTIGIT−mTregs and that they likely repre-
sent a portion of the FOXP3− and possibly FOXP3+ cells in the popula-
tion. It is likely that in the absence of IL-2, the lack of proliferation from
the IL-6RhiTIGIT− subset is due to the potent suppressive effect of the
Tregs present in the same sorted population.
3.5. IL-6RhiTIGIT− Tregs isolated ex vivo have a Th17 transcriptional proﬁle
To investigate the transcriptional proﬁle of IL-6RhiTIGIT− mTregs,
we assessed the mRNA expression of 579 immune genes in sorted
cells from nine healthy donors (Table 2 in Ref. [45]). The expression of
TIGIT and IL-6R was assessed post-sorting and displayed a distinct ex-
pression in the respective subsets, indicating a very high level of purity
(Fig. 1D in Ref. [45]). We found that ex vivo IL-6RhiTIGIT− mTregs
showed a distinct Th17 transcriptional signature (Fig. 5A), marked by
the speciﬁc higher expression of the Th17 lineage discrimination tran-
scription factor RORγt (encoded byRORC). The observed Th17 signature
was also deﬁned by higher expression of additional Th17 genes, includ-
ing KLRB1 (CD161), CCR6, IL1R1 and IKZF3 (AIOLOS) [48–51], in IL-
6RhiTIGIT−mTregs (Fig. 5A,B). The results obtained at the transcription-
al level were consistent with the results obtained at the protein level, as
illustrated by the immunophenotyping of two Th17 signature surface
receptors, CD161 and CCR6 (Fig. 5 in Ref. [45]). To investigate if the ex-
pression of IL-6R discriminates cells displaying a Th17 transcriptional
signature within the TIGIT− mTreg population, we compared the ex-
pression of these two canonical Th17 markers in both IL-6Rhi and IL-
6R−/int (corresponding to the lower 70th percentile of IL-6R expression
in Tregs) TIGIT− mTregs (Fig. 6A in Ref. [45]). The frequency of both
CD161+ (44.0% versus 27.1%, P=1.0 × 10−14) and CCR6+ (78.8% versus
57.4%, P = 5.4 × 10−5; Fig. 6B in Ref. [45]) cells were signiﬁcantly in-
creased in the IL-6Rhi subset, indicating that elevated IL-6R expression
provides a better discrimination of Th17 Tregs (together with some
Th17 Teffs) within the TIGIT− compartment.
Furthermore, we also noted the increased expression of LAG3 and
IL10 (Fig. 5C), which have been described as markers of the IL-10-
producing FOXP3− Tr1 subset [52,53], and could also account for a pro-
portion of the cells with a methylated FOXP3 TSDR and a lack of FOXP3
expression in this population. Conversely, we found that the expression
of two transcription factors, LEF1 and TCF7 (encoding TCF1), previously
shown to co-ordinately repress the Th17 transcriptional program [54,
55], were speciﬁcally downregulated in IL-6RhiTIGIT− mTregs
(Fig. 5D). These data demonstrate a strong transcriptional commitment
of IL-6RhiTIGIT− mTregs to the Th17 phenotype. We observed a con-
comitant downregulation of the Treg genes FOXP3 and IKZF2 (HELIOS)
(Fig. 5E), and an upregulation of CTLA4 (Fig. 5A), which is consistent
with the observed decreased frequency of FOXP3+ and HELIOS+ cells,
but increased frequency of CTLA-4+ cells within IL-6RhiTIGIT−mTregs
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ularly pronounced when comparing the IL-6RhiTIGIT− to IL-6RhiTIGIT+
mTregs, which are a subset of highly activated Tregs, as evidenced by
the elevated expression of HLA class II genes (Fig. 7 in Ref. [45]).
3.6. In vitro activated IL-6RhiTIGIT− Tregs produce high levels of cytokines
and increased expression of the pro-inﬂammatory IL-1β and IL-23
receptors
To examine the effect of activation on the induction of the transcrip-
tional programme of IL-6RhiTIGIT− mTregs, we next assessed the ex-
pression of the 579 immune genes on sorted cells from the three Treg
subsets from four healthy donors in response to in vitro stimulation
with PMA and ionomycin (Table 3 in Ref. [45]). Consistent with their
Th17 transcriptional proﬁle, IL-6RhiTIGIT− mTregs produced a large
number of different cytokines,most notably Th17-speciﬁc cytokines, in-
cluding IL-17, IL-22 and CCL20 (Fig. 6A,B). Notably, IL-6RhiTIGIT−
mTregs were also found to produce very high levels of the anti-
inﬂammatory cytokine IL-10 (Fig. 6A,B). Importantly, the expression
of genes that were speciﬁcally upregulated in IL-6RhiTIGIT− mTregs
were found to be remarkably similar to a set of signature genes that
were uniquely expressed in a population of mouse lamina propria
Tregs [56]. This set of genes included the expression of signature
genes such as CTLA4, LAG3, CCR2, CCR5, IRF4, MAF and IKZF3 (AIOLOS)
ex vivo (Table 2 in Ref. [45]), and the expression of IL10 and GZMB
upon in vitro stimulation (Table 3 in Ref. [45]), which suggests that
the IL-6RhiTIGIT−mTregs we identify in circulation in humans share a
similar origin to the murine intestinal Tregs.
In vitro stimulated IL-6RhiTIGIT−mTregs produced higher levels of
certain cytokines than even conventional CD45RA−memory Teffs (e.g.
6.1-fold and 15.1-fold increase in the expression of IL17A and IL10 com-
pared to Teffs; Fig. 6A,B), whilst expressing lower levels of the Treg
genes IKZF2 (HELIOS) and TNFRSF9 (CD137) (Fig. 6C). In addition to cy-
tokine production, in vitro stimulation also induced the expression of
IL1R1 and IL23R on IL-6RhiTIGIT− mTregs (Fig. 6D), suggesting an in-
creased sensitivity to IL-1β and IL-23 signalling.
To investigate the functional heterogeneity within IL-6RhiTIGIT−
mTregs, we then examined the production of IL-17 and IL-10 at the
single-cell level by ﬂow cytometry following in vitro activation. Given
that IL-6R is shed upon in vitro activation, we could not use it to delin-
eate IL-6RhiTIGIT− mTregs, but instead focused on the total TIGIT−
mTreg population. Consistent with previous observations [57,58], we
showed that the HELIOS− fraction of TIGIT− mTregs contained the
vast majority of cytokine-producing Tregs (Fig. 7A,B). In contrast,
there was a much higher level of heterogeneity among the FOXP3-
deﬁned subsets, with both FOXP3+ and FOXP3− Tregs showing the abil-
ity to produce IL-10 and IL-17 (Fig. 7A,B). We found that themajority of
IL-10 and IL-17 producing cells were distinct (Fig. 7C), indicating that
cellular heterogeneity among HELIOS− Tregs is responsible for the pro-
duction of these two very distinct cytokines observed in IL-6RhiTIGIT−
mTregs (Fig. 6B). In addition, we assessed the expression of RORγt by
ﬂow cytometry on a subset of 4 healthy donors. Of note, the frequency
of RORγt+ cells was distinctly increased on IL-6RhiTIGIT− mTregs
(44.2%) as compared to TIGIT−mTregs with lower expression of IL-6R
(15.0%; Fig. 8A in Ref. [45]), indicating that elevated expression of IL-
6R is critical for the delineation of the Th17 signature with TIGIT−
mTregs. Furthermore, in agreement with the observation that IL-17-
producing cells are mainly FOXP3+, we also found that the frequency
of FOXP3+ cellswas strongly increased on RORγt+ (78.0%) as comparedFig. 2. IL-6Rhi Tregs are activated antigen-experienced cells and show reduced expression o
(depicted in blue) and IL-6Rhi (depicted in red) Tregs in healthy donors (N = 22). (B) Plot d
6Rlo and IL-6Rhi Tregs. (C) Data shown depicts the frequencies (GeoMean ± 95% CI) of the pr
mTregs. (D) Data depict the frequency of three Treg markers, HELIOS, FOXP3 and TIGIT in
Fluorescence Intensity (MFI) of the assessed markers in the two subsets from one illustrativ
signed rank test, comparing the frequency of the assessed immune phenotypes between the ILto their RORγt− counterparts (51.7%) within IL-6RhiTIGIT−mTregs, and
was very similar to the frequency on TIGIT+ mTregs (83.4%; Fig. 8B in
Ref. [45]).
3.7. IL-6RhiTIGIT− Treg chemokine expression proﬁle is consistent with a
tissue-homing effector Treg subset
To assess the potential tissue-homing properties of IL-6RhiTIGIT−
mTregs, we next investigated their chemokine receptor proﬁle ex vivo
(Fig. 9A in Ref. [45]). Using the deﬁnition of themain Th cell lineages de-
scribed previously [59], we conﬁrmed the speciﬁc increase in the Th17
subset within IL-6RhiTIGIT− mTregs, with a concomitant decrease in
the frequencies of the Th2 and Th22 subsets compared to conventional
TIGIT+mTregs (Fig. 9B in Ref. [45]). In contrast, the frequency of the Th1
subset was not signiﬁcantly altered in the different Treg populations
(Fig. 9B in Ref. [45]). Analysis of the expression of the individual chemo-
kine receptors also revealed that the proﬁle of IL-6RhiTIGIT− mTregs
wasmore similar to TIGIT+mTregs than to the TIGIT−mTregs express-
ing lower levels of IL-6R (IL-6R−/int), which were more similar to mem-
ory Teff cells (Fig. 9C in Ref. [45]). Furthermore, we noted that the
frequency of CCR4+ cells was particularly elevated within IL-
6RhiTIGIT− mTregs (96.8%); CCR4 has previously been described as a
marker of highly suppressive, tissue-inﬁltrating, effector Tregs [60].
Similarly, we also observed that the frequency of another receptor re-
cently shown to mark the more suppressive effector FOXP3+ Tregs,
CD15s [61], was much higher for IL-6RhiTIGIT− mTregs (46.8%), com-
pared with IL-6R−/int mTregs (15.8%).
Transcriptional analysis also identiﬁed the increased expression of
two additional chemokine receptors, CCR2 and CCR5, among the topdif-
ferentially expressed genes in ex vivo isolated IL-6RhiTIGIT− mTregs
(Table 2 in Ref. [45]). To investigate the gut-homing capacity of IL-
6RhiTIGIT− mTregs, we also assessed the expression of integrins α4
and β7 associated with migration to the colon, and the small intestine
homing marker CCR9 (Fig. 10A,B in Ref. [45]). Expression of both the
α4 monomer and the α4β7 heterodimer as well as CCR9, were in-
creased on IL-6RhiTIGIT−mTregs (Fig. 10C in Ref. [45]), demonstrating
that a portion of IL-6RhiTIGIT−mTregs possess the capacity to migrate
to the gut.
4. Discussion
The critical role of Tregs inmediating protection from autoimmunity
has led to many studies over the past decades, which have vastly con-
tributed to our knowledge about this immune subset, and to the devel-
opment of therapeutic strategies targeting Tregs. However, with the
development of novel genomics [46] and proteomics tools [62], it is be-
coming apparent that there is phenotypic and functional heterogeneity
among Tregs, which could lead to unexpected outcomes in clinical trials
targeting Tregs in transplantation, tumour therapy and in autoimmune
diseases.
In the present studywe performed in-depth immunophenotyping of
the expression of IL-6R on the human CD4+CD127lowCD25+ T cell com-
partment ex vivo. Although IL-6R has been shown to be expressed by
human Tregs [35,63], there is limited data describing its expression on
different Treg subsets, and there has been no attempt to characterise
the function of Tregs stratiﬁed by IL-6R expression. This is due to a com-
bination of factors, namely the limited range of expression of IL-6R on
human T cells, the large genetically-regulated inter-individual variation
in expression levels [38], the high sensitivity of IL-6R to shedding inf FOXP3, HELIOS and CD25. (A) Gating strategy for the delineation of circulating IL-6Rlo
epicts the frequency (GeoMean ± 95% CI) of the CD45RA−memory compartment in IL-
oliferation marker Ki-67 and the activation marker PD-1 in CD45RA− IL-6Rlo and IL-6Rhi
CD45RA− IL-6Rlo and IL-6Rhi mTregs. Histograms depict the distribution of the Mean
e donor. P values were calculated using a two-tailed paired non-parametric Wilcoxon
-6Rlo and IL-6Rhi Treg subsets.
Fig. 3. Reduction of Treg markers is restricted to the IL-6RhiTIGIT− subset. (A) Gating strategy for the delineation of the three assessed mTreg subsets: IL-6Rlo (depicted in blue), IL-
6RhiTIGIT+ (depicted in green) and IL-6RhiTIGIT− (depicted in red). (B, C) Frequencies within the Treg subsets (GeoMean ± 95% CI) of the Treg markers HELIOS and FOXP3 (B), and
CD25 and CTLA-4 (C) were assessed by ﬂow cytometry in freshly isolated PBMCs from 33 healthy donors. P values were calculated using a two-tailed paired non-parametric Wilcoxon
signed rank test.
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of the antibodies and cytometric ﬂuorescent labels to reach the greatest
sensitivity of detection of the receptor, all of which hamper the precise
quantitative measurement of this receptor by ﬂow cytometry in
humans. Our results therefore provide the ﬁrst detailed phenotypic
and functional characterisation of IL-6R-expressing CD127lowCD25+ Tcell subsets in humans, and support a role of IL-6 signalling on the sta-
bility and function of differentiated Treg subsets.
We identiﬁed a subset of circulating IL-6RhiTIGIT− CD127lowCD25+
T cells (designated as IL-6RhiTIGIT−mTregs)with a Th17 transcriptional
proﬁle, marked by the expression of the RORγt transcription factor, high
CTLA-4 expression, and the capacity to produce high levels of both pro-
Fig. 4. IL-6RhiTIGIT−mTregs are highly suppressive in vitro and display a Treg epigenetic proﬁle. (A) Suppressive capacity of the threemTreg subsets was assessed by the ability to supress
the proliferation of autologous CD45RA− Teff cells in vitro. Data shown depict the suppressive capacity (mean ± SEM) of the assessed mTreg subsets at diluting Treg:Teff ratios, and was
obtained from sorted cells from six independent donors. P valueswere calculated using a two-tailed paired t-test comparing the suppressive capacity of IL-6RhiTIGIT− to the IL-6RloTIGIT+
and IL-6RhiTIGIT+ counterparts. *P b 0.05; **P b 0.01; ***P b 0.001. (B) Data depict the frequency of reads demethylated at eight or nine of the nine interrogated CpG sites in the FOXP3 Treg-
speciﬁc demethylation region (TSDR) or at seven out of seven CpG sites in the CTLA4 locus. The data were obtained from sorted cells from three independent healthy male donors. Hor-
izontal bars depict themedian of thedemethylated reads in each group. (C) Proliferative capacity of sorted (i) IL-6RhiTIGIT+ (depicted in green), (ii) IL-6RhiTIGIT− (depicted in red), (iii) IL-
6RloTIGIT+ (depicted in blue) mTregs, and (iv) CD127+CD25−CD45RA− Teff cells (depicted in black) was assessed in response to in vitro stimulation with α-CD3/CD28 beads and
100 U/ml exogenous IL-2. Data (mean± SEM)were obtained from cells sorted from three independent donors. Proliferation and suppressive capacity were calculated using the Division
Index in FlowJo, setting 0% suppression as the condition with the respective Teffs cultured in the absence of Tregs.
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in Table 1). Although we note that a population of Th17 Tregs has been
previously described in humans [19–22], our data reﬁnes the charac-
terisation of this subset, and reveals a remarkably consistent Th17
transcriptional proﬁle and the capacity to produce a wide range of
cytokines, most notably Th17-type cytokines, upon in vitro
stimulation.
A key ﬁndingwas the observation that IL-6RhiTIGIT−mTregs are ex-
tremely effective at suppressing the proliferation of autologous Teffs
in vitro, even more so than IL-6RhiTIGIT+ mTregs, which exhibit all the
classic hallmarks of conventional suppressive Tregs. This observationis even more remarkable if we consider that a proportion of the IL-
6RhiTIGIT−mTreg population consists of non-anergic FOXP3−memory
Teffs. A limitation of the current study is that, owing to the cellular het-
erogeneity of the IL-6RhiTIGIT− CD127lowCD25+ T cell population, we
cannot exclude the possibility that the Th17 transcriptional signature
is caused by a subset of CD127lowCD25+ Th17 Teff cells. The observation
that the majority of IL-17-producing cells, as well as RORγt+ IL-
6RhiTIGIT−mTregs, are present in the FOXP3+ compartment supports
the regulatory nature of IL-6RhiTIGIT−mTregs displaying a Th17 proﬁle,
as illustrated by the good correlation that we observed between the fre-
quency of FOXP3+ cells and the frequency of FOXP3 TSDR
Fig. 5. Ex vivo IL-6RhiTIGIT−mTregs show a distinct Th17 transcriptional proﬁle compared to conventional IL-6RloTIGIT+mTregs. (A) Volcano plot depicts the differential expression of 579
immune genes in IL-6RhiTIGIT− and IL-6RloTIGIT+ mTregs sorted ex vivo from nine healthy donors using NanoString. (B–D) Illustrative examples depicting the expression (GeoMean ±
95% CI) of (i) Th17 signature genes (marked in red), including RORC (RORγt), KLRB1 (CD161), IL1R1, IKZF3 (AIOLOS), and CCR6 (B); (ii) Tr1 signature genes LAG3 and IL10 (marked in
purple) (C); (iii) the transcription factors LEF1 and TCF7 (TCF1) (marked in blue), involved in the suppression of Th17 differentiation; and (iv) Treg signature genes (marked in green),
including TIGIT, HELIOS and FOXP3 (D), which were most differentially expressed in IL-6RhiTIGIT−mTregs compared to their IL-6RloTIGIT+ counterparts. Sorting markers used for the
ﬂow-sort puriﬁcation of the assessed Treg subsets are marked in black. P values were calculated using two-tailed paired non-parametric Wilcoxon signed rank tests, comparing the
normalised NanoString read counts between IL-6RhiTIGIT− and IL-6RloTIGIT+ mTregs.
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whether the IL-17 secreting RORγt+ FOXP3+ T cells display a
demethylated TSDR. Therefore, we cannot formally exclude the possi-
bility that IL-17-secreting RORγt+ FOXP3+ cells represent a subset of
activated memory Teffs with a methylated TSDR, and account for the
difference in the frequency between FOXP3+ cells at the protein level
and the frequency of TSDR demethylated cells within IL-6RhiTIGIT−
mTregs.
In addition, IL-6RhiTIGIT−mTregs were found to produce very high
levels of the anti-inﬂammatory cytokine IL-10, which is a key mediator
of Treg suppression in vivo, suggesting the possibility that a small
proportion of Tr1 Tregs present in the FOXP3− fraction of the IL-
6RhiTIGIT−mTreg population could account for the increased suppres-
sive capacity of this population, through the production of high levels
of IL-10. Further work will be necessary to dissect the cellular and func-
tional heterogeneity of this population at the single-cell level, and toFig. 6. IL-6RhiTIGIT− Tregs display a signiﬁcant cytokine-producing potential upon in vitro activ
IL-6RhiTIGIT−mTregs and: (i) IL-6RloTIGIT+ mTregs; (ii) IL-6RhiTIGIT+ mTregs; or (iii) memor
genes shown in the ﬁgure represent the subset of 40 genes that were both: (i) signiﬁcantly up
differentially expressed (adjusted P b 10−4) between activated IL-6RhiTIGIT− and IL-6RloT
6RhiTIGIT−mTregs, including both pro- (IL-17A, IL-22 and CCL20) and anti-inﬂammatory (IL-
activated IL-6RhiTIGIT− Tregs, including IKZF2 (encoding for HELIOS) and TNFRSF9. (D) The
upregulated in activated IL-6RhiTIGIT−mTregs.investigate the TSDR demethylation of the cytokine-producing subsets.
Despite the cellular heterogeneity of IL-6RhiTIGIT−mTregs, our ﬁndings
have important implications for the clinical studies exploring the ex-
pansion of CD4+ CD127lowCD25+ T cells for the treatment of autoim-
mune diseases, and identify a population of IL-6RhiTIGIT− T cells
within this compartment containing a signiﬁcant fraction of activated
effector Tregs, which likely mediate their suppression in part by IL-10
production [65] and CTLA-4 binding to the co-stimulatory molecules
CD80 and CD86 [66,67]. Furthermore, the elevated expression of CD25
compared to memory Teff cells, combined with the high sensitivity to
IL-2 in vivo suggests that IL-6RhiTIGIT−mTregs are also able to mediate
their suppression mechanism through IL-2 consumption [65].
These results are consistent with a previous study, characterising a
subset of HELIOS−mTregs marked by the expression of the IL-1R and
the transcription factor AIOLOS in humans, which were found to be
more suppressive than conventional HELIOS+ Tregs ex vivo [58]. Ination. (A) Heatmap depicts the differential expression of 40 selected genes between sorted
y Teff cells from four healthy donors, upon in vitro activation with PMA+ ionomycin. The
regulated (adjusted P b 10−5) in IL-6RhiTIGIT−mTregs upon in vitro simulation; and (ii)
IGIT+ mTregs. (B) Illustrative examples of cytokine genes upregulated in activated IL-
10) cytokines. (C) Illustrative examples depicting downregulated Treg signature genes in
expression of the IL-23 and IL-1 receptor genes (IL23R and IL1R1) were also speciﬁcally
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pacity, through a mechanism dependent on the expression of the IL-1R
[58]. Furthermore, another study has described a subset of FOXP3+
Tregs marked by the expression of CD161with high in vitro suppressive
capacity [68]. Similarly to the IL-6RhiTIGIT− mTregs described here,
these CD161+FOXP3+ Tregs also displayed the capacity to produce IL-
17 following in vitro activation, and contained predominantly cells
demethylated at the FOXP3 TSDR [68]. In contrast to the data from
Pesenacker et al., we characterise a more puriﬁed subset of HELIOS−
IL-6RhiTIGIT−mTregs, and use a more quantitative method [46] to as-
sess the exact frequency of demethylated cells in this subset. The iden-
tiﬁcation of a suppressive HELIOS−TIGIT− mTreg population is
particularly striking given that TIGIT+ HELIOS+ Tregs are traditionally
thought to harbour themost suppressive Treg subset [69–71]. However,
we note in two of these studies [69,71] that naive Tregs were not ex-
cluded from the sorted TIGIT− Tregs used in the suppression assays
and, therefore,may have diluted the suppressive capacity, when consid-
ered on a per cell basis, of the mTregs within the sorted TIGIT− Treg
population.
From an evolutionary perspective, there is evidence pointing to a
common developmental pathway in the differentiation of both
induced-Treg and Th17 lineages [27], suggesting that Th17 Tregs
could play an important role in the regulation of the immune responses
and commensal bacteria composition in the gut [72]. This is consistent
with the recent data showing that the composition of intestinal bacterial
commensals is critical in regulating the frequency of a highly suppres-
sive subset of RORγt+ Tregs in mice [23,24], which are thought to regu-
late the interplay between commensal and pathogenic bacteria and the
host immune system in the gut, while preventing chronic inﬂammation.
Furthermore, another recent study in mice has shown that RORγt+
FOXP3+ cells represent a stable Treg lineage with epigenetic marks of
conventional RORγt− FOXP3+ Tregs, and are potent suppressors of in-
ﬂammation in a colitis model [25]. The transcriptional proﬁle of these
murine RORγt+ FOXP3+ Tregs is very similar to the human IL-
6RhiTIGIT−mTregs described in our study, including the expression of
Th17 signature genes but also of Treg effector genes such as IL10 and
CTLA4.
Our ﬁndings suggest that a similar gut-resident T cell subset ex-
ists in humans [73], which is mobilised and expanded by IL-2 treat-
ment and consequently becomes more detectable in the blood. In
agreement with this hypothesis, IL-6RhiTIGIT− mTregs displayed a
remarkably similar transcriptional proﬁle with a population of
Tregs resident in the mucosal tissues [56], which strongly supports
that IL-6RhiTIGIT− mTrsgs are located primarily in the intestine and
mesenteric lymph nodes. In agreement with this hypothesis, IL-
6RhiTIGIT− mTregs displayed a chemokine receptor proﬁle consis-
tent with a tissue-homing T cell subset, including the elevated ex-
pression of markers such as CCR2, CCR4, CCR5 and CCR6 and the
adhesion marker CD15s, as well as the speciﬁc upregulation of the
prototypical small intestine (CCR9) and colon (α4β7) homing recep-
tors. These data demonstrate the tissue-homing properties of IL-
6RhiTIGIT− mTregs, and their capacity to migrate to the gut, there-
fore supporting their potential intestinal nature, which is similar to
their murine intestinal RORγt+ FOXP3+ Treg analogues. Although
the expansion of Tregs in circulation in response to IL-2 is not re-
stricted to the IL-6RhiTIGIT− subset, we hypothesise that this subset
could be particularly relevant for regulating Th17 responses, and ex-
pansion and trafﬁcking in response to IL-2 signalling by IL-
6RhiTIGIT− cells suggest an important role in the regulation of tissue
inﬂammation and autoimmune reactions. One possibility that has
been suggested in a mouse model is that IL-10 production by
FOXP3+ Tregs is key to promote equilibrium with pro-
inﬂammatory IL-17-producing RORγt+ Th17 effector cells [74]. Our
observation that IL-10 is expressed at high levels by IL-6RhiTIGIT−
mTregs, suggests that they represent a major IL-10-producing Treg
subset in humans, and play a critical role in the regulation of the IL-17-mediated immune responses at the sites of infection, which is
key to maintain the homeostasis between commensal bacteria and
invading pathogens at mucosal barrier surfaces.
In the context of human autoimmune disease, IL-17-producing
FOXP3+ Tregs with in vitro suppressive capacity have been shown to
be recruited to the intestinal mucosa in active Crohn's disease patients
[75], to the inﬂamed joints of juvenile idiopathic arthritis (JIA) patients
[68] and to peripheral blood of rheumatoid arthritis patients [76]. In ad-
dition, in psoriasis patients, IL-6R-expressing Tregs have been previous-
ly shown to be recruited to the inﬂamed skin, where they co-localise
with the pathogenic IL-17 producing Th17 effector cells [35]. These ob-
servations are consistent with the recruitment of activated Th17-
signature positive Tregs with suppressive function to the sites of infec-
tion to prevent or limit Th17 effector tissue damage. An intriguing ques-
tion that remains to be addressed is the potential effect of prolonged
exposure to pro-inﬂammatory signals on the differentiation and func-
tion of these RORγt+ FOXP3+ Tregs, particularly in the setting of chron-
ic inﬂammation.We have shown that mTregs can signal through the IL-
6R by activating pSTAT3, and have previously demonstrated that elevat-
ed expression of IL-6R on CD4+ T cells translates to increased IL-6 sig-
nalling [38]. Furthermore, IL-6 is known to relieve the FOXP3-
mediated suppression of RORγt [30], leading to the disruption of the
balance of RORγt and FOXP3 expression in IL-6RhiTIGIT−mTregs, and
to the concomitant instability of FOXP3 expression in these cells. We
therefore hypothesise that in genetically-susceptible individuals at the
IL6R locus, the increased IL-6 signalling potential increases the sensitiv-
ity of IL-6RhiTIGIT−mTregs to IL-6, resulting in the loss of regulatory po-
tential and to the trans-differentiation into pathogenic IL-17-producing
ex-Tregs [77–79].
In summary, our ﬁndings identify a subset of HELIOS−FOXP3+
Tregs, which can be detected in vivo based on the expression of two sur-
face markers, IL-6R and TIGIT, and show that subcutaneously adminis-
tered IL-2 can promote the expansion and trafﬁcking of these cell
subsets into circulation. Although the frequency of these cells is usually
low in peripheral blood, ranging from 0.4% to 1.4% of total circulating
CD45RA−memory CD4+ T cells, their frequency is expanded with sin-
gle doses of IL-2 of around 400,000 IU/m2 [15]. Moreover, the strong
in vitro suppressive capacity of IL-6RhiTIGIT− mTregs coupled with
their potential to produce a diversity of pro- and anti-inﬂammatory cy-
tokines, suggests that their frequency should be carefully monitored,
particularly in autoinﬂammatory diseases, in which chronic inﬂamma-
tion could promote themigration of these cells from the gut to inﬂamed
tissues. As clinical studies aiming to expand Tregs becomemore preva-
lent, another important application of these markers will be to assess
preferential expansion of speciﬁc Treg and additional CD127lowCD25+
Teff subsets, and inform on disease-speciﬁc dosing and patient selec-
tion, especially in conditions where IL-17 is a cause of tissue damage
[80]. Our ﬁndings also suggest a biological mechanism underpinning
the genetic association of the IL6R with human inﬂammatory diseases,
whereby in genetically susceptible individuals, increased IL-6 signalling
could impair the regulatory function of a tissue-resident Treg subset
with potent suppressive potential. These data provide a rationale for
speciﬁc targeting of thismolecular pathway in diseases genetically asso-
ciated with the IL6R locus, rather than non-speciﬁc blockade of IL-6 sig-
nallingwhich brings with it an increased risk of infection that might not
be acceptable in the context of T1D in children.Funding
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